Healwell AI Leadership Presents Growth Strategy to Institutional Investors

Healwell AI presents at ROTH Conference, showcasing 427% revenue growth to $103.8M in 2025, operational profitability, and a 2026 plan for 50% AI segment growth and 10% EBITDA margin.

Fresh from announcing record-breaking financial results, Healwell AI's executive team is taking its story directly to major investors. The company is presenting at the ROTH Conference in California this week, aiming to secure institutional capital. A central challenge for management is articulating the company's current dichotomy: explosive operational growth paired with significant bottom-line losses.

Strategic Ambitions for 2026

A key focus of the investor pitch is the roadmap for the current fiscal year, 2026. Management has outlined aggressive targets, including a goal to expand its Artificial Intelligence and Data Science segment by over 50 percent. Furthermore, Healwell AI plans to significantly enhance its profitability. Leveraging synergy effects from the integration of subsidiary Orion Health, the company is targeting an adjusted EBITDA margin of approximately 10 percent by year-end.

The conference provides a direct platform to mobilize funding for this next phase. With a cash position of $18.6 million and strategic holdings in the xAI ecosystem, Healwell possesses a financial buffer. The critical task now is to demonstrate that the projected margin improvement can be realized throughout the year.

Financial Performance: A Story of Two Metrics

The company's recent annual report for 2025 supplies the core data for these investor discussions. Revenue skyrocketed by 427 percent to $103.8 million, illustrating a steep growth trajectory. Concurrently, Healwell achieved a milestone by reaching operational profitability on an adjusted EBITDA basis, which came in at $2.3 million.

However, this positive operational picture is contrasted by a substantial IFRS net loss of $39.1 million. The costs associated with the company's rapid expansion continue to weigh heavily on the unadjusted results. This discrepancy is a key point of evaluation for shareholders, a factor reflected in the current share price of $0.88.

Global Reach and Clinical Validation

To bolster investor confidence, management is highlighting the successful international scaling of its business. Healwell AI's solutions are now deployed not only across North America but also in the Middle East. Through the network of its Orion Health subsidiary, the company has expanded its reach to more than 70 major clients across eleven countries.

The company also points to peer-reviewed validation of its proprietary DARWEN AI platform as evidence that its technology is both commercially scalable and medically robust. Healwell recently announced the publication of the 47th academic paper related to its platform, underscoring its scientific foundation.